With 38 million Americans suffering from migraines, today's FDA approval of Eli Lilly's (LLY - Get Report) preventative migraine drug Emgality is another step closer to getting patients' their lives back.

Sadly, about 75% of those sufferers are women, in their 30s and 40s, says Christi Shaw, president, Lilly Bio-Medicines when we spoke with her at the NYSE.

Emgality is now the third migraine drug available. Amgen (AMGN - Get Report) and Novartis (NVS - Get Report) have one, as does Teva TEVA.

And patients with commercial insurance are candidates to receive Emgality for up to 12 months free as part of Lilly's patient support program.

Shaw discussed all of this plus she got personal with us and talked about how she stepped down away from big pharma for a year when her sister got sick so she could see her through clinical trials.

But taking time to be a caregiver, gave her an entirely different perspective, one that she has since brought back to her current role.

Watch now for more.